Project Grant 2143160
Award Date
2/15/22
Completion Date
1/31/27
Dollars Obligated
$436K
Federal Grant Program
47.041
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21287, USA
Similar Awards
This $256,000 National Science Foundation project grant supports the development of novel antibody-brush polymer conjugates with high drug-to-antibody ratios by Window Therapeutics, Inc. The goal is to create the next generation of antibody-drug conjugates for cancer immunotherapy through research and development of antibody-brush polymer conjugates that can load up to 100 drugs per antibody. These conjugates aim to enable immunotherapies to treat immunoresistant cancers like colorectal cancer...
This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...
This $508,785 federal Project Grant award from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) supports research at Columbia University to investigate how the chemical composition and mechanical properties of biomaterials can be optimized to improve the production and function of T cells for use in cancer immunotherapy. The project aims to gain fundamental knowledge on how nutrient transport, particularly oxygen availability, within these biomaterials affects T cell...
This $224,582 Project Grant awarded by the National Science Foundation (NSF) under the Computer and Information Science and Engineering program (CFDA 47.070) aims to develop a computational framework that integrates knowledge-driven and data-driven artificial intelligence approaches to recommend effective immunotherapeutic cell designs for cancer treatment. The framework will utilize large language models and graph neural networks to extract knowledge from scientific literature and represent...
This National Science Foundation (NSF) Engineering Program (CFDA 47.041) project grant, awarded to Duke University, aims to decode how single-cell phenotypic heterogeneity arises and can be precisely controlled in T cells, which are critical for cancer immunotherapy. The $574,808 award, effective May 1, 2025 through April 30, 2030, will leverage cutting-edge technologies like spatial proteomic multiplexed imaging, in vitro cell tracking, and engineered biomaterial artificial antigen-presenting...
This $353,843 Project Grant awarded by the National Science Foundation (NSF) under the Engineering program (CFDA 47.041) will support the development of programmable and dynamically-responsive bacterial therapeutics for cancer immunotherapy. The project aims to create a novel biosensing system in E. coli bacteria that can recognize extracellular cancer antigens and respond with therapeutic payloads. In parallel, the researchers will engineer bacteria with improved tumor colonization capabilities...
The National Science Foundation (NSF) awarded a 5-year, $480,730 CAREER grant under the Engineering program (CFDA 47.041) to Tufts University to evaluate the impact of modifying antibodies with unique amino acids on the regulation of matrix metalloproteinase (MMP) activity. The goal is to establish principles of "chemically diversified" antibodies that enable next-generation protease inhibitor discovery. The project will integrate noncanonical amino acids and yeast display technology...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding of $695,916 to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel inhibitors of the NSMASE2 enzyme for enhancing the effectiveness of immune checkpoint inhibitors in cancer treatment. The project aims to synthesize and test PDDC analogs to improve the potency, solubility, and pharmacokinetics of NSMASE2 inhibitors. Promising...
This National Science Foundation (NSF) Engineering program (CFDA 47.041) project grant award to the University of North Carolina at Greensboro (UNC-G) aims to develop synthetic antigen-presenting cells (SAPCs) that can precisely control the immune response. The $199,998 award, with a performance period from Jul 1, 2025 to Jun 30, 2027, will support research to elucidate how the size of SAPCs influences their function and develop size-tunable SAPCs that enhance T cell activation and adaptive...
This $256,000 National Science Foundation project grant supports the generation of directly active monoclonal antibodies to CD19 for the treatment of B-cell malignancies by Welt Bio-Molecular Pharmaceutical, LLC. The grant funds research under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop novel monoclonal antibody therapies that could provide more affordable and less toxic options for leukemias and lymphomas compared to current drugs. Specifically, the awardee...